Avalo (AVTX) CLO Varki Paul Receives 80,000-Share Award

What Happened
Varki Paul, Chief Legal Officer of Avalo Therapeutics (AVTX), received a derivative award on February 26, 2026 covering 80,000 shares. The filing reports the acquisition price as $0.00 (derivative instrument), and no cash was exchanged at grant. This is a time‑based equity award (stock option) that vests over multiple years rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (filed within the SEC filing window).
• Instrument/amount: Award of options/derivative covering 80,000 shares; acquisition price reported as $0.00.
• Vesting: 25% vests on February 26, 2027; the remainder vests in equal monthly installments over the following three years, subject to continued service (footnote F1).
• Shares owned after transaction: Not disclosed in the filing.
• No sale or cashless exercise reported; this is a grant of equity compensation.

Context
This is a standard time‑based equity grant to an executive; it does not represent a purchase or sale in the open market. Such grants are common for employee retention and do not, by themselves, indicate insider buying or selling intent.